Top

Published in:

Open Access 01-09-2014 | Review

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Authors: Gábor Holló, Jouni Vuorinen, Juhani Tuominen, Teppo Huttunen, Auli Ropo, Norbert Pfeiffer

Published in: Advances in Therapy | Issue 9/2014

Abstract

A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F_2α analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin–timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (>13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav^® (Alcon, Fort Worth, USA) and Ganfort^® (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.

Available only for authorised users

Stjernschantz J. From PGF_2α -isopropyl ester to latanoprost: a review of the development of Xalatan. Investig Ophthalmol Vis Sci. 2001;42:1134–45.

Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S13–33.PubMedCrossRef

Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337–45.PubMedCrossRef

Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S34–40.PubMedCrossRef

Davies SS, Ju WK, Neufeld AH, Abran D, Chemtob S, Roberts LJ 2nd. Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003;19:45–54.PubMedCrossRef

Camras CB, Toris CB, Sjöquist B, et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111:2193–8.PubMedCrossRef

Woodward DF, Jones RL, Narumiya S. International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev. 2011;63:471–538.PubMedCrossRef

Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–76.PubMedCrossRef

Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice. Br J Ophthalmol. 2007;91:673–6.PubMedCrossRefPubMedCentral

10.

Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601–4.PubMedCrossRef

11.

Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979;97:656–8.PubMedCrossRef

12.

Juzych MS, Zimmerman TJ. Beta blockers. In: Zimmerman TJ, Kooner KS, Sharil M, Fechtner RD, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven Publishers; 1997. p. 261–275.

13.

Pfeiffer N. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe’s Arch Clin Exp Ophthalmol. 2002;240:893–9.CrossRef

14.

Higginbotham EJ, Feldman R, Stiles M, Dubiner H, For the Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy. One-year randomized trial. Arch Ophthalmol. 2002;120:915–22.PubMedCrossRef

15.

Schuman JS, Kats GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140:242–50.PubMedCrossRef

16.

Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004 %/timolol 0.5 % fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140:1–7.PubMedCrossRef

17.

Hommer A, Ganfort^® Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatorpost 0.03 %/timolol 0.5 % with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53–62.

18.

Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, For the Ganfort® Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17:211–6.PubMedCrossRef

19.

Lewis RA, Gross RL, Sall KN, Schiffman RM, Liu CC, Batoosingh AL, For the Ganfort^® Investigators Group II. The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized, parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2010;19:424–6.PubMedCrossRef

20.

Pfeiffer N, Traverso CE, Lorenz K, et al., For the Preservative-free Tafluprost Fixed Combination Study Group. A six month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015 % and timolol 0.5 % versus each of its individual preservative-free components. Adv Ther 2014 (submitted).

21.

Patel SC, Spaeth GL. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg. 1995;26:234–6.

22.

Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–6.PubMedCrossRef

23.

Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–40.PubMedCrossRef

24.

Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737–47.PubMedCrossRef

25.

Olander K, Zimmerman TJ, Downes N, Schoenfelder J, For the Xalacom^®/Latanoprost Study Group. Switching from latanoprost to the fixed combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther. 2004;26:1619–29.PubMedCrossRef

26.

Franks WA, Renard JP, Cunliffe IA, Rojanapongpun P. A 6-week double-masked, parallel-group study of the efficacy and safety of travoprost 0.004 % compared with latanoprost 0.005 %/timolol 0.5 % in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:332–9.PubMedCrossRef

27.

Zhihong L, Mingchang Z, Yizhen H, et al. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension. Chin Med J. 2014;127:905–10.CrossRef

28.

Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45–52.PubMedCrossRef

29.

Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004 %/timolol 0.5 % ophthalmic solution compared to travoprost 0.004 % ophthalmic solution and timolol 0.5 % dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14:392–9.PubMedCrossRef

30.

Holló G, Hommer A, Antón López A, Ropo A. Efficacy, safety and tolerability of preservative-free fixed combination of tafluprost 0.0015 %/timolol 0.5 % versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30:468–75.PubMedCrossRef

31.

Goldberg I, Gil Pina R, Lanzagorta-Aresti A, Schiffman RM, Liu C, Bejanian M. Bimatoprost 0.03 %/timolol 0.5 % preservative-free ophthalmic solution versus bimatoprost 0.03 %/timolol 0.5 % (Ganfort^®) for glaucoma or ocular hypertension: a 12-week randomized controlled trial. Br J Ophthalmol. 2014;98:926–931.

32.

Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS, United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128:165–72.PubMedCrossRef

33.

Astin M. A study on the vascular effects of prostaglandin F_2α and latanoprost in the eye with special reference to surface hyperemia after topical administration. Compr Summ Uppsala Univ dissertations Faculty of Medicine 1998. p.179.

34.

Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501–15.PubMedCrossRef

35.

Konstas AG, Voudouragkaki IC, Boboridis KG, et al. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014;31:592–603.PubMedCrossRef

36.

Konstas AG, Mikropoulos DG, Embesliis TA, et al. 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol fixed combinations in exfoliative glaucoma. Eye (Lond). 2010;24:1606–13.CrossRef

37.

Konstas AG, Tsironi S, Vakalis AN, et al. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. Acta Ophthalmol. 2009;87:71–6.PubMedCrossRef

38.

Konstas AG, Holló G, Mikropoulos D, et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94:209–13.PubMedCrossRef

39.

Diestelhorst M, Larsson L-I, for the European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70–6.PubMedCrossRef

40.

Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004 %/timolol 0.5 % to once-daily latanoprost 0.005 %/timolol 0.5 % in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:183–90.PubMed

41.

Palmberg P, Kim EE, Kwok KK, Tressler CS, Canada and United States Fixed Combination Latanoprost/Timolol Study Group. A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur J Ophthalmol. 2010;20:708–18.PubMed

42.

Teus MA, Miglior S, Laganovska G, et al. Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:629–36.PubMedCrossRefPubMedCentral

43.

Kitazawa Y, Smith P, Sasaki N, Kotake S, Bae K, Iwamoto Y. Travoprost 0.004 %/timolol 0.5 %-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond). 2011;25:1161–9.CrossRef

Title: Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
Authors: Gábor Holló
Jouni Vuorinen
Juhani Tuominen
Teppo Huttunen
Auli Ropo
Norbert Pfeiffer
Publication date: 01-09-2014
Publisher: Springer Healthcare
Published in: Advances in Therapy / Issue 9/2014
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-014-0151-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2014

Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Efficacy and Tolerability of Fixed-Combination Brinzolamide/Timolol in Latin American Patients with Open-Angle Glaucoma or Ocular Hypertension Previously on Brimonidine/Timolol Fixed Combination

A Cohort Study of the Relationship Between Anger and Chronic Spontaneous Urticaria

Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis

Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page